Category Archives: Co-morbidities

Harm reduction for smokers living with HIV

2021

Tobacco use is now a leading cause of death in people living with HIV in the USA. Increasing cessation rates in this group is a public health priority, yet the...

APOL1 risk variants and the development of HIV-associated nephropathy

2021

HIV-associated nephropathy (HIVAN) remains a concern among untreated HIV patients, notably of African descent, as patients can reach end-stage renal disease within 3Aÿyears. Two variants (G1 and G2) of the...

Cardiometabolic complications in youth with perinatally acquired HIV in the era of antiretroviral therapy

2021

PURPOSE OF REVIEW: Antiretroviral therapy (ART) scale-up has dramatically reduced rates of pediatric HIV mortality and morbidity. Children living with perinatally acquired HIV (PHIV) are now expected to live through...

Allopregnanolone and neuroHIV: Potential benefits of neuroendocrine modulation in the era of antiretroviral therapy

2021

Forty years into the HIV pandemic, approximately 50% of infected individuals still suffer from a constellation of neurological disorders collectively known as ‘neuroHIV.’ Although combination antiretroviral therapy (cART) has been...

Coronary artery calcification and plaque characteristics in people living with HIV: A systematic review and meta-analysis

2021

Background Studies have reported that people living with HIV have higher burden of subclinical cardiovascular disease, but the data are not adequately synthesized. We performed meta‐analyses of studies of coronary...

Sociodemographic predictors associated with the spectrum of non-opportunist neuroretinal disease of non-infectious etiology in patients with HIV/AIDS: A scoping review

2021

BACKGROUND: Non-infectious retinal disease, even in the HAART era, continues to be one of the most common diagnoses in patients with HIV, with prevalences of up to 27% of cases....

The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving TAF/FTC/DTG, TDF/FTC/DTG or TDF/FTC/EFV

2021

Objective: Integrase inhibitors, including dolutegravir (DTG), are associated with weight gain and obesity, especially when combined with tenofovir alafenamide (TAF). Obesity increases the risk of adverse pregnancy outcomes (APOs). This study...

Gut microbiome in people living with HIV is associated with impaired thiamine and folate syntheses

2021

People living with HIV have a high incidence of cardiovascular and neurological diseases as comorbid disorders that are commonly linked to inflammation. While microbial translocation can augment inflammation during HIV...

Perinatal outcomes in women living with HIV-1 and receiving antiretroviral therapy — A systematic review and meta-analysis

2021

Introduction Antiretroviral therapy-naïve pregnant women living with HIV are at an increased risk for adverse pregnancy outcomes. It remains controversial whether this risk persists with antiretroviral therapy. We conducted a...

Cardiac adiposity as a modulator of cardiovascular disease in HIV

2021

BACKGROUND: With the number of people living with human immunodeficiency virus (HIV) steadily increasing, cardiovascular disease has emerged as a leading cause of non-HIV related mortality. People living with HIV...

Cardiovascular risk assessment in people living with HIV: A systematic review and meta-analysis of real-life data

2020

BACKGROUND: People living with HIV (PLWHIV) have a 2-fold higher risk of having a cardiovascular event than HIV-negative individuals. OBJECTIVE: The objective of this article is to estimate the pooled...

Treatment of pre- and confirmed cervical cancer in HIV-seropositive women from developing countries: A systematic review

2020

BACKGROUND: Cervical cancer has become a major public health challenge in developing countries with a reported age-standardised incidence rate of about 17.9/100,000/year and lifetime risks approaching 1 in 20 in...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!